In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sorin launches Ovatio ICDs (implantable cardioverter defibrillators) in Japan:

This article was originally published in Clinica

Executive Summary

Sorin Group has launched its Ovatio DR implantable cardioverter defibrillators (ICDs) in Japan. The Milan, Italy company claims that the Ovatio product line comprises the world's smallest such devices, and hence that their thinness suits for Japanese body size. The single and dual chamber models, Ovatio VR 6250 and DR 6550 ICD, have received regulatory and reimbursement approval from the Japanese health ministry (MHLW). Both models are immediately available. The dual chamber Ovatio DR includes a feature designed to reduce unnecessary stimulation in the right ventricle, thus decreasing the risk of heart failure and atrial fibrillation, as well as a component intended to protect patients from inappropriate shocks.

You may also be interested in...



Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Change Is Coming In Health Care, If Not Yet At The Speeds Of Other Consumer Industries

The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.

Is Pharma Too Introspective To Be Truly Innovative?

The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation shares his thoughts. 

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel